Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Total Current Liabilities (2018 - 2025)

10x Genomics' Total Current Liabilities history spans 8 years, with the latest figure at $153.5 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 30.45% year-over-year to $153.5 million; the TTM value through Dec 2025 reached $153.5 million, up 30.45%, while the annual FY2025 figure was $153.5 million, 30.45% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $153.5 million at 10x Genomics, up from $147.3 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $153.5 million in Q4 2025 and bottomed at $94.4 million in Q1 2022.
  • The 5-year median for Total Current Liabilities is $112.7 million (2021), against an average of $116.8 million.
  • The largest YoY upside for Total Current Liabilities was 104.09% in 2021 against a maximum downside of 31.05% in 2021.
  • A 5-year view of Total Current Liabilities shows it stood at $110.4 million in 2021, then increased by 18.67% to $131.0 million in 2022, then decreased by 2.9% to $127.2 million in 2023, then fell by 7.49% to $117.6 million in 2024, then surged by 30.45% to $153.5 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Total Current Liabilities are $153.5 million (Q4 2025), $147.3 million (Q3 2025), and $112.2 million (Q2 2025).